<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164269">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959504</url>
  </required_header>
  <id_info>
    <org_study_id>ILMN001</org_study_id>
    <nct_id>NCT00959504</nct_id>
  </id_info>
  <brief_title>Detection of Factor V Leiden G1691A and Factor II (Prothrombin) G20210A Point Mutations in DNA</brief_title>
  <official_title>VeraCode Genotyping Test for Factor V and Factor II on the BeadXpress System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Illumina, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Illumina, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As an external validation test of the performance of the VeraCode Genotyping Test for Factor
      V and Factor II on the BeadXpress System, clinical trials will be conducted at three sites.
      This study will assess genotyping accuracy as compared to bidirectional sequencing and
      genotyping reproducibility across variables such as user, day, and site.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">275</enrollment>
  <condition>Detection and Genotyping of Factor V and Factor II Point Mutations</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient samples will be leftover EDTA-anticoagulated whole blood from patients referred
        for Factor V and/or Factor II testing.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient samples will be leftover EDTA-anticoagulated whole blood from patients
             referred for Factor V and/or Factor II testing.

        Exclusion Criteria:

          -  There are no applicable exclusion criteria for this test, since the genomic sequence
             will not vary by ethnicity, gender, age or disease. Inappropriately stored blood
             samples will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 7, 2011</lastchanged_date>
  <firstreceived_date>August 13, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Don Ellis, Sr. Director of Quality</name_title>
    <organization>Illumina</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
